Deep Blue Medical Advances

What Deep Blue Medical Advances does

Deep Blue Medical Advances is a privately held medical device company founded in March 2015 and headquartered in Durham, North Carolina, with a secondary office in San Francisco. The company develops and commercializes next-generation surgical implants and techniques that address soft tissue failure in hernia repair, with a portfolio being extended into breast reconstruction and aesthetic surgery applications.

The company's core technology is the T-Line Hernia Mesh, a large-pore, medium-weight polypropylene mesh featuring integral suture-like extensions that distribute fixation force across 15 times more surface area than traditional sutures, yielding approximately 275% greater anchoring strength and reducing suture pull-through ("cheese-wiring") that drives hernia recurrence. The platform is anchored by a patented lock-stitch surgical technique and protected by 21 issued patents licensed from Duke University and NC State University, with five years of clinical validation evidenced by 18 peer-reviewed publications, 27 conference presentations, and 20,000+ implants across 45 U.S. clinical sites with no adverse events reported. Adjacent products include T-Line Mini (for umbilical hernias), Anchor Clips (fixation device), and pipeline assets T-Line TCS (Tissue Control Suture), T-Line Scaffold for Breast Surgery, and biosynthetic and coated composite mesh variants. FDA 510(k) clearance was received in August 2020 for open onlay approach, with sublay indication added in December 2022.

The company operates an enterprise field sales motion selling directly to hospitals and surgeons via phone, email, and clinical site engagement, supplemented by conference participation across hernia, plastic surgery, and cosmetic surgery events. Revenue is generated through hardware sales of mesh and fixation devices under quote-based hospital procurement pricing. As of April 2026 the company has raised approximately $13.1 million in equity across a 2022 Series A1 led by BayMed Venture Partners and a 2026 oversubscribed Series A, alongside roughly $4.6 million in non-dilutive NIH grants, and is led by CEO Bill Perry, Founder/CMO Howard Levinson MD, and COO Lou Fuqua.

Name

Deep Blue Medical Advances

Legal name

Deep Blue Medical Advances, Inc.

Website

https://deepbluemedical.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Deep Blue Medical Advances is a Durham-based medical device company that develops the T-Line Hernia Mesh, a polypropylene implant with integral suture-like extensions that prevents fixation failure in hernia repair and other soft tissue surgeries. It sells directly to hospitals and surgeons across approximately 45 U.S. clinical sites.

Ownership category

akta.pro rank

Product category

Surgical Hernia Mesh Devices

NAICS

Electronic Connector Manufacturing (334417)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Compression Therapy for Venous/Lymphedema (Bandages, Wraps, Garments) (HLAHALAF)

Keywords

• Hernia mesh devices
• Soft tissue repair
• Surgical mesh products
• Abdominal wall reconstruction
• Medical device manufacturing

Headquarters

HQ city

Durham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. T-Line Hernia Mesh Sales: Direct sales of T-Line Hernia Mesh products to hospitals and surgeons for hernia repair procedures. One-time purchase of surgical mesh devices with various size configurations.
2. Product Portfolio Expansion: Revenue from additional products including T-Line Mini, biosynthetic absorbable T-Line Mesh, coated composite versions, Anchor Clips, and T-Line Scaffold for Breast Surgery.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Deep Blue Medical Advances develops and sells the T-Line Hernia Mesh, a large-pore mid-weight polypropylene surgical mesh with integral suture-like extensions designed for ventral, incisional, and umbilical hernia repair. The mesh extensions eliminate the mesh-suture-tissue interface failure point by providing 15x more surface area and approximately 275% greater fixation strength than conventional sutures, available in multiple size configurations for open onlay and sublay surgical approaches.

Product overview

Deep Blue Medical Advances offers a portfolio of surgical devices for soft tissue surgery and hernia repair. The core product is the T-Line® Hernia Mesh (with T-Line Mini as a smaller variant), which features integral suture-like mesh extensions to prevent fixation failure. Supporting products include the Anchor Clips fixation device and the Lock Stitch Technique. The platform is expanding through products in development: T-Line® TCS (Tissue Control Suture), T-Line Scaffold for Breast Surgery, and biosynthetic and coated composite versions of the T-Line Hernia Mesh. The company targets the $1.1B+ global hernia device market and broader soft tissue surgery applications with a purpose-built platform addressing suture pull-through.

Differentiator

Problem solved

Functional benefit

Products and services

• T-Line Hernia Mesh Large-pore, medium-weight polypropylene hernia mesh with integral suture-like mesh extensions designed to eliminate mesh-suture-tissue interface failure and provide approximately 275% greater fixation strength than conventional sutures. Available in multiple sizes with 3, 7, or 14 extensions per side, ranging from 4.5cm x 6.0cm to 29.0cm x 20.5cm, for ventral hernia repair via open onlay or sublay approach in adults. FDA 510(k) cleared.
• T-Line Mini Smaller version of T-Line Hernia Mesh with 3 extensions per side, designed for ventral hernia repair where a smaller mesh is needed, such as umbilical hernias and small defects. Features grasping needle with suture-like extension.

Quantifiable outcome

• 275% greater fixation strength compared to conventional mesh-suture attachment
• +5 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Duke UniversitycoreTechnology or Integration · 1 January 2015Technology licensed from Duke University - IP licensed from Duke and NCSU, multiple filings in 4 patent areas. Founder Howard Levinson is a plastic surgeon and researcher at Duke University.
• North Carolina State UniversitycoreTechnology or Integration · 1 January 2015Technology licensed from NCSU as part of company's IP portfolio development. University partnerships for technology transfer and research collaboration.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ethicon (Johnson & Johnson): Ethicon is the market-leading hernia mesh franchise within Johnson & Johnson, offering a broad portfolio of polypropylene, biologic, and composite meshes used in ventral, inguinal, and incisional hernia repair. Directly comparable as the dominant incumbent competing against T-Line Hernia Mesh across the same hospital and surgeon customer base.
• Medtronic: Medtronic's Surgical Solutions business (built on the Covidien acquisition) sells hernia mesh and fixation devices, including composite and resorbable products. Direct competitor with comparable product positioning, broad hospital contracts, and global sales reach that T-Line is competing against for surgeon adoption.
• BD (Becton Dickinson): BD's Surgery unit (formerly Bard/Davol) is one of the largest hernia mesh franchises globally, with products spanning ventral, inguinal, and complex abdominal wall reconstruction. Direct peer with established surgeon relationships and procurement scale that competes head-to-head for hernia repair case volume.
• Cook Medical: Cook Medical manufactures surgical meshes including biologic grafts used in hernia repair and abdominal wall reconstruction. Direct competitor with overlapping surgeon customers and similar hospital procurement channels, particularly in complex hernia and academic center segments.
• B. Braun: B. Braun's Aesculap division offers surgical mesh and suture fixation products for hernia and soft tissue repair. Direct competitor with global hospital distribution and a portfolio comparable in scope to T-Line Hernia Mesh in the open onlay and sublay segments.
• Smith+Nephew: Smith+Nephew's Advanced Wound Management and Sports Medicine businesses include surgical meshes and biologic scaffolds used in soft tissue repair. Direct peer with comparable abdominal wall and soft tissue reconstruction offerings and overlapping hospital customer base.
• Conmed: Conmed manufactures hernia mesh and complementary fixation devices (tacks, sutures, anchors) used in laparoscopic and open hernia repair. Direct peer with product overlap in mesh-plus-fixation combinations analogous to T-Line Mesh and Anchor Clips portfolio.
• Integra LifeSciences: Integra LifeSciences offers regenerative tissue technologies and surgical implants used in soft tissue repair, hernia, and reconstructive surgery. Direct peer with comparable focus on soft tissue reinforcement and similar surgeon customer base in abdominal wall and plastic surgery segments.
• W. L. Gore & Associates: Gore's Medical Products division sells GORE-TEX based surgical meshes and bioabsorbable products (e.g., SYNECOR, BIO-A) used in hernia and abdominal wall reconstruction. Direct peer competing on material science and clinical performance, with a similar emphasis on differentiated biomaterials.

Emerging players

• Tepha: Tepha is a medical device company developing resorbable polymer-based surgical meshes and soft tissue repair products. Comparable as a smaller, innovation-driven mesh company targeting similar clinical problems around hernia and soft tissue reinforcement, though at an earlier commercial stage with a different material platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deep Blue Medical Advances